Anzeige
❌
Mehr »
Freitag, 20.11.2026 - Börsentäglich über 12.000 News

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
BI

WKN: A2QJRW | ISIN: SE0015244520 | Ticker: BIX0
Frankfurt
20.11.26 | 08:26
0,189 Euro
-17,20 % -0,039
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOINVENT INTERNATIONAL AB Chart 1 Jahr
5-Tage-Chart
BIOINVENT INTERNATIONAL AB 5-Tage-Chart
RealtimeGeldBriefZeit
0,1760,19420:13

Aktuelle News zur BIOINVENT Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
09.11.BioInvent International: BioInvent to Participate in Upcoming Investor Conferences263LUND, SE / ACCESS Newswire / November 9, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that representatives...
► Artikel lesen
05.11.BioInvent International AB: BioInvent announces final terms for the Rights Issue of approximately SEK 430 million and informs that the Issue is fully guaranteed by additional top guarantee undertakings165Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other jurisdiction where such...
► Artikel lesen
BIOINVENT Aktie jetzt für 0€ handeln
05.11.Transgene S.A.: First Patient Dosed in Phase 1 Trial Evaluating Transgene's and BioInvent's BT-001 in Patients with Rectal Cancer1
28.10.BioInvent International AB: BioInvent International AB: Interim report January - September, 2026150"Our clinical portfolio remains focused on two targets, TNFR2 and Fc?RIIB, but with a current priority on BI-1808 in cancers where patients have few effective options. With the planned rights issue...
► Artikel lesen
28.10.BioInvent International AB: BioInvent resolves on a rights issue of approximately SEK 430 million subject to approval by an extraordinary general meeting and earlier publication of interim report January - September 2026208Not for release, publication or distribution, directly or indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan, Singapore, South Africa or any other jurisdiction where such...
► Artikel lesen
27.10.BioInvent International: Invitation to Presentation of BioInvent's Interim Report January - September 2026321LUND, SE / ACCESS Newswire / October 27, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV) invites investors, analysts, and the press to a presentation of the interim report January-September...
► Artikel lesen
24.10.BioInvent International: BioInvent's BI-1808 and KEYTRUDA Induce Durable Responses in Heavily Pretreated Platinum-Resistant Ovarian Cancer959BioInvent International (STO:BINV) - Updated efficacy data in 34 evaluable patients with a chemotherapy-free regimen; randomized Part C will add BI-1808 to the new standard of care24% objective response...
► Artikel lesen
19.10.BioInvent International: BioInvent To Present BI-1808 Data in Platinum-Resistant Recurrent Ovarian Cancer at ESMO 20261.928BioInvent International (STO:BINV) - Poster with the title "From Modest to Meaningful: Targeting TNFR2 with BI-1808 to Unlock Checkpoint Inhibitor Efficacy in Platinum-Resistant Recurrent Ovarian Cancer...
► Artikel lesen
15.10.BioInvent International: BioInvent Announces Publication of First-in-Human BI-1808 Data in Clinical Cancer Research618BI-1808 monotherapy demonstrated an excellent safety profile and evidence of single-agent anti-tumor activity, correlating with tumor-infiltrating CD8+ T cells and inducing antitumor immunity.Translational...
► Artikel lesen
12.10.BioInvent International AB Announces that its CFO will Retire in 2027380LUND, SE / ACCESS Newswire / October 12, 2026 / BioInvent International AB ("BioInvent") (STO:BINV), a leader in the discovery of novel immunomodulatory antibodies, today announced that the company's...
► Artikel lesen
27.08.BioInvent International AB: Interim report January - June 2026575"During the second quarter, both of our lead programs generated clinical data that further strengthened their competitive positioning. BI-1808 (anti-TNFR2) reported new results in two distinct indications...
► Artikel lesen
20.08.BioInvent International: BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research997Preclinical manuscript that characterizes the mechanism of action, broad antitumor efficacy, and immune-activating properties of BI-1808 and BI-1910 across diverse tumor microenvironmentsData demonstrates...
► Artikel lesen
07.08.BioInvent International: BioInvent Receives FDA Fast Track Designation for BI-1808 for the Treatment of Ovarian Cancer996FDA Fast Track Designation granted for BI-1808, a first-in-class anti-TNFR2 antibody, for the treatment of ovarian cancer.BI-1808 in combination with pembrolizumab demonstrated a 24% confirmed ORR and...
► Artikel lesen
28.07.BioInvent International: BioInvent Publication in JECCR: Tailored FcyR Blockade with BI-1206 and BI-1607 Enhances Cancer Antibody Therapies and Overcomes Resistance in Preclinical Models655LUND, SE / ACCESS Newswire / July 28, 2026 / BioInvent International (STO:BINV)Preclinical proof-of-concept data support two distinct FcyR-blockade strategies to enhance cancer antibody therapies and...
► Artikel lesen
17.07.BioInvent International: BioInvent's BI-1808 Abstract from Modest to Meaningful in Platinum-Resistant Ovarian Cancer Accepted for Poster Presentation at ESMO 2026625LUND, SE / ACCESS Newswire / July 17, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that its...
► Artikel lesen
11.06.BioInvent International: BioInvent's TNFR2 Antibody BI-1808 Delivers Meaningful Responses and Immune Activation as Single Agent and in Combination with KEYTRUDA in Advanced CTCL871BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)BI-1808 monotherapy achieves...
► Artikel lesen
11.06.BioInvent International: BioInvent's BI-1206 Triplet Achieves 83% Response Rate in Refractory NHL with Improved Safety vs. SOC648BioInvent will host an in-person KOL lunch briefing (11:45 a.m. - 2:00 p.m. CEST / 5:45 - 8:00 a.m. EDT) in conjunction with EHA 2026 Congress today (virtual event link here)83% ORR across all evaluable...
► Artikel lesen
01.06.BioInvent International: BioInvent to Host a KOL Event in Stockholm on June 11, 2026, to Discuss Updated BI-1206 & BI-1808 Data in Hematology719LUND, SE / ACCESS Newswire / June 1, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it...
► Artikel lesen
21.05.BioInvent International: BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA in Advanced Ovarian Cancer at ASCO931BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by...
► Artikel lesen
20.05.BioInvent International: BioInvent to Host Virtual KOL Event to Discuss BI-1808 for the Treatment of Ovarian Cancer, on May 27, 20261.105LUND, SE / ACCESS Newswire / May 20, 2026 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a leader in the discovery of novel immune-modulatory antibodies, today announced that it...
► Artikel lesen
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1